The recent identification of mTOR as a downstream target of Fbxw7 [27], [28] suggests that germline or somatic changes may affect tumor responses to known inhibitors of the mTOR pathway such as rapamycin, and such investigations are presently in progress in this laboratory. This evidence concerns the gene FBXW7 and neoplasm.